查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984095

骨髓惡性腫瘤檢測市場：依技術、檢體類型、檢測模式、應用和最終用戶分類－2026-2032年全球市場預測

Hematologic Malignancies Testing Market by Technology, Sample Type, Test Mode, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，骨髓惡性腫瘤檢測市場價值將達到 63.8 億美元，到 2026 年將成長至 71 億美元，到 2032 年將達到 152.8 億美元，年複合成長率為 13.29%。

主要市場統計數據
基準年 2025 63.8億美元
預計年份：2026年 71億美元
預測年份 2032 152.8億美元
複合年成長率 (%) 13.29%

簡潔而權威的框架，闡述了診斷技術創新、臨床需求和檢查室現代化如何重塑骨髓惡性腫瘤檢測過程。

骨髓惡性腫瘤檢測處於快速發展的生物學、精準診斷和不斷變化的臨床工作流程的交匯點。分子譜分析的最新進展，以及細胞遺傳學和免疫表現型分析能力的提升，已經徹底改變了診斷流程，並促進了診斷分類的改善。隨著臨床醫生和檢查室負責人對更快、更具實用性的檢測結果的需求日益成長，檢查室生態系統也在積極響應，構建日益整合的平台和擴充性的檢測組合，涵蓋傳統和先進的檢測方法。

技術整合、營運現代化和分散式檢查模式如何從根本上改變診斷實​​務和商業性方法。

骨髓惡性腫瘤檢測領域正經歷著變革性的轉變，這主要得益於技術融合、臨床範式的轉變以及支付者和監管機構不斷變化的期望。分子診斷，特別是基於定序的方法，正擴大與細胞遺傳學和流式細胞技術聯合應用，從而產生多維度的診斷結果。同時，免疫組織化學檢測也在不斷改進，以適應液體和組織樣本的檢測，從而支持互補性生物標記的評估，提高診斷的準確性，並有助於標靶治療的選擇。

基於證據的分析，探討 2025 年美國關稅措施將如何重塑診斷實驗室的供應鏈、採購經濟和業務永續營運。

美國在2025年實施或提案的關稅措施將對骨髓惡性腫瘤檢測的價值鏈產生複雜影響，波及試劑供應、設備採購及進口耗材的經濟效益。對診斷組件徵收關稅可能會增加檢測設備和一次性試劑的總體成本，迫使採購負責人重新與供應商談判合約、尋找替代貨源或加強與本地製造商的合作。因此，依賴跨境供應關係的檢查室可能需要調整庫存策略，並投資長期計畫以維持服務的連續性。

綜合細分分析揭示了技術模式、臨床適應症、醫療保健環境、檢體工作流程和檢測模式如何協調一致並定義診斷重點。

以細分市場為中心的洞察揭示了診斷能力與臨床需求在技術、應用、終端使用者、檢體類型和檢測模式等領域的交匯點。從技術整體情況診斷格局包括細胞遺傳學、流式細胞技術、免疫組織化學和分子診斷。在細胞遺傳學領域，螢光原位雜合反應(FISH) 和核型分析仍然是檢測結構變異和非整倍體的核心技術；而免疫組織化學則涵蓋了用於細胞抗原譜分析的液基和組織基方法。分子診斷進一步細分為針對特定位點的螢光雜合反應、用於分析全面突變譜的次世代定序以及用於靶向、高靈敏度檢測的聚合酵素鏈鎖反應(PCR)，從而形成一個支持診斷準確性的多層次工具包。

一份詳細的、針對特定區域的評估報告，分析了基礎設施、還款計畫和製造能力如何推動世界各地市場採用差異化的採用和商業化策略。

骨髓惡性腫瘤檢測的區域趨勢反映了各主要地區在醫療基礎設施、報銷體系、法規環境和創新能力上的差異。在美洲，以醫療網路和參考實驗室為主導的中心化實驗室以及注重處理能力和全面檢測組合的競爭格局，往往主導了先進分子和細胞遺傳學檢測的普及。相較之下，歐洲、中東和非洲（EMEA）地區的情況則較為複雜，既有成熟的高績效中心，又受到國家報銷政策和區域特定監管路徑的限制，導致檢測普及受到限制，因此需要製定量身定做的推廣策略和夥伴關係模式。

企業層面的策略分析表明，平台整合、分子診斷領域的專家創新者以及服務實驗室正在重塑競爭定位和夥伴關係模式。

骨髓惡性腫瘤檢測領域的企業級趨勢反映了成熟診斷公司、新興分子診斷公司和專業服務檢查室之間的平衡。大型診斷儀器製造商持續投資於平台整合、工作流程自動化和擴展檢測項目，以滿足醫院網路和高通量參考檢查室的需求。同時，小規模的分子診斷公司則專注於小眾檢測組合、先進的定序工作流程以及生物資訊能力，從而實現精準醫療應用。儀器製造商與試劑專家之間的策略合作日益普遍，以創造出能夠減少營運摩擦並加速檢查室部署的捆綁式解決方案。

為檢查室管理人員和診斷供應商提供可操作且優先考慮的建議，以建立供應鏈彈性、數位化整合和臨床協作，從而實現永續部署。

產業領導者應優先考慮一套能夠平衡短期營運連續性和長期能力建構的連貫措施。首先，供應鏈多元化並與供應商密切合作可以降低關稅和物流風險。檢查室和供應商應共同了解關鍵組件的依賴關係，並在可能的情況下尋找替代來源或建立本地製造夥伴關係。其次，對自動化和資訊技術的投資應旨在減少人工操作，並實現可擴展的分析工作流程，整合細胞遺傳學、流式細胞技術、免疫組織化學和分子數據，從而產生一致的臨床報告。

我們採用透明的混合方法研究途徑，結合與關鍵相關人員的訪談、技術檢驗和背景分析，得出可靠且可操作的結論。

本分析的調查方法採用了一種多方面混合方法，結合了對實驗室經理、臨床專家、採購經理和行業高管的訪談，以及對監管指南、技術檢驗文獻和上市公司資訊披露資訊的系統性回顧。在資料整合過程中，重點在於運用三角驗證法，將供應商的說法、檢查室的實踐模式和臨床指南進行比對，以確保觀察結果反映的是實際操作情況，而非供應商的宣傳。案例研究展示了檢查室如何在血液和骨髓檢體中，以及在檢查室檢測和就地檢驗模式下，部署綜合檢測策略。

簡潔扼要的結論強調了綜合診斷、供應彈性和策略商業化如何決定臨床影響和營運永續性。

總之，骨髓惡性腫瘤檢測正在發展成為一個整合的多模態生態系統，細胞遺傳學、流式細胞技術、免疫組織化學和分子診斷技術在此融合，提供更豐富、更具臨床應用價值的資訊。檢查室和供應商必須投資於自動化、互通性和以臨床醫生為中心的報告系統，同時應對價格敏感的供應鏈變化、複雜的監管環境以及區域部署差異等挑戰。技術的融合以及對白血病、淋巴瘤、多發性骨髓瘤和骨髓發育不良症候群日益成長的需求，為優先考慮臨床效用和運營擴充性的差異化解決方案創造了機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章骨髓惡性腫瘤檢測市場：依技術分類

  • 細胞遺傳學
    • 螢光原位雜合反應
    • 核型分析
  • 流式細胞技術
  • 免疫組織化學
    • 液態基
    • 組織基礎
  • 分子診斷
    • 螢光原位雜合反應
    • 次世代定序
    • 聚合酵素鏈鎖反應

第9章 依標本類型分類的骨髓惡性腫瘤檢體市場

  • 血
  • 骨髓

第10章骨髓惡性腫瘤檢測市場（依檢測模式分類）

  • 檢查室基地
  • 照護端

第11章骨髓惡性腫瘤檢測市場：依應用領域分類

  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 骨髓發育不良症候群

第12章骨髓惡性腫瘤檢測市場：依最終用戶分類

  • 學術和研究機構
  • 醫院和診所
  • 測試機構

第13章骨髓惡性腫瘤檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章骨髓惡性腫瘤檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章骨髓惡性腫瘤檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國骨髓惡性腫瘤檢測市場

第17章：中國骨髓惡性腫瘤檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • ICON PLC
  • Illumina, Inc.
  • Invitae Corporation
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Nikon Instruments
  • Ortho Clinical Diagnostics
  • PerkinElmer Corporation
  • QIAGEN NV
  • Siemens AG
  • Sysmex Corporation
Product Code: MRR-2E76C3E47FC1

The Hematologic Malignancies Testing Market was valued at USD 6.38 billion in 2025 and is projected to grow to USD 7.10 billion in 2026, with a CAGR of 13.29%, reaching USD 15.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.38 billion
Estimated Year [2026] USD 7.10 billion
Forecast Year [2032] USD 15.28 billion
CAGR (%) 13.29%

A concise and authoritative framing of how diagnostic innovation, clinical demand, and laboratory modernization are reshaping hematologic malignancy testing pathways

Hematologic malignancies testing sits at the intersection of rapidly evolving biology, precision diagnostics, and shifting clinical workflows. Recent advances in molecular profiling, coupled with enhanced cytogenetic and immunophenotyping capabilities, have transformed diagnostic pathways and deepened the granularity of diagnostic classifications. As clinicians and laboratory leaders seek to deliver faster, more actionable results, the laboratory ecosystem has responded with increasingly integrated platforms and more scalable assay portfolios that span traditional and advanced modalities.

Consequently, testing workflows are no longer siloed; they converge across multiple diagnostic modalities to inform treatment selection, risk stratification, and minimal residual disease monitoring. Transitional innovations in automation and informatics facilitate higher throughput and better data harmonization, while parallel needs for quality management and regulatory compliance continue to shape laboratory adoption strategies. Taken together, these dynamics underscore a diagnostic environment in which clinical value is driven by analytic performance, operational efficiency, and the ability to translate complex data into clear therapeutic decision points.

How technological convergence, operational modernization, and decentralized testing models are fundamentally transforming diagnostic practices and commercial approaches

The landscape for hematologic malignancies testing is experiencing transformative shifts driven by technological convergence, changing clinical paradigms, and evolving payer and regulatory expectations. Molecular diagnostics, particularly sequencing-based assays, are increasingly deployed alongside cytogenetics and flow cytometry to create multidimensional diagnostic readouts. At the same time, immunohistochemistry practices have adapted to liquid and tissue formats to support complementary biomarker assessment, enhancing diagnostic certainty and supporting targeted therapy selection.

In parallel, laboratory operations are undergoing modernization through automation, standardized protocols, and cloud-enabled data platforms that enable secure cross-institutional collaboration. Together with improvements in sample processing for blood and bone marrow, these changes reduce time to result while increasing diagnostic resolution. Moreover, the shift toward point-of-care testing in select scenarios is prompting manufacturers and clinical labs to rethink assay design for robustness and decentralization. These converging trends are catalyzing new service models, reshaping vendor partnerships, and expanding opportunities for value-based diagnostic strategies.

An evidence-based analysis of how 2025 United States tariff actions are reshaping supply chains, procurement economics, and operational resilience for diagnostic laboratories

United States tariff measures enacted or proposed in 2025 introduce complex implications for the hematologic malignancies testing value chain, affecting the economics of reagent supply, instrument procurement, and imported consumables. Tariffs on diagnostic components can increase landed costs for laboratory instrumentation and single-use reagents, which in turn pressures procurement managers to renegotiate supplier contracts, explore alternative sourcing, or accelerate local manufacturer engagement. Consequently, laboratories that rely on cross-border supply relationships may need to revise inventory strategies and invest in longer-lead planning to maintain service continuity.

Furthermore, tariffs can spur accelerated regionalization of supply chains and encourage investment in domestic manufacturing capacity for critical reagents and disposables. However, this shift requires time and capital, and it may not address specialized components produced by a limited number of global manufacturers. From a regulatory and contracting perspective, laboratories and vendors must also reassess pricing models and reimbursement negotiations to reflect altered cost structures. In short, tariff dynamics in 2025 act as a catalyst for supply chain diversification, operational contingency planning, and closer alignment between purchasing strategies and clinical service commitments.

Integrated segmentation analysis revealing how technology modalities, clinical indications, care settings, sample workflows, and testing modes align to define diagnostic priorities

Segmentation-centric insights illuminate where diagnostic capability and clinical demand intersect across technologies, applications, end users, sample types, and test modes. Based on technology, the diagnostic landscape includes cytogenetics, flow cytometry, immunohistochemistry, and molecular diagnostics; within cytogenetics, both fluorescence in situ hybridization and karyotyping remain central to structural variant and aneuploidy detection, while immunohistochemistry spans liquid-based and tissue-based approaches to cellular antigen profiling. Molecular diagnostics further breaks down into fluorescence in situ hybridization for targeted loci, next-generation sequencing for comprehensive mutational landscapes, and polymerase chain reaction for focused, high-sensitivity detection, creating a layered toolkit that supports diagnostic precision.

Application-driven demand concentrates on leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, each presenting distinct biomarker and monitoring requirements that favor particular testing modalities and workflows. End users such as academic and research institutes, hospitals and clinics, and reference laboratories adopt these modalities with differing intensity and scale, influencing investments in automation and informatics integration. Sample type considerations center on blood and bone marrow, which dictate pre-analytical handling and assay selection, while test mode divides workflows into laboratory-based and point-of-care environments, shaping turnaround expectations and decentralization strategies. Altogether, segmentation analysis highlights where technology choices, clinical use cases, and care settings converge to define priorities for assay development, laboratory deployment, and commercial engagement.

A nuanced regional assessment detailing how infrastructure, reimbursement, and manufacturing capacity drive differentiated adoption and commercialization strategies across global markets

Regional dynamics in hematologic malignancies testing reflect differences in healthcare infrastructure, reimbursement frameworks, regulatory environments, and capacity for innovation across major geographies. In the Americas, institutional networks and reference laboratories often lead in adopting advanced molecular and cytogenetic testing, supported by centralized labs and a competitive vendor landscape that emphasizes throughput and comprehensive assay portfolios. By contrast, Europe, Middle East & Africa exhibit a heterogeneous mix of mature centers of excellence and constrained settings where adoption is influenced by national reimbursement decisions and region-specific regulatory pathways, prompting tailored rollout strategies and partnership models.

Asia-Pacific demonstrates rapid uptake of diagnostic innovation in urban centers, driven by growing clinical volumes, investments in laboratory automation, and expanding domestic manufacturing that can reduce dependence on imports. Across regions, interoperability, workforce training, and supply chain robustness remain cross-cutting priorities that determine how quickly new assays translate into routine clinical practice. Consequently, stakeholders seeking to scale testing solutions must adapt commercialization, regulatory, and support models to the nuanced needs of each geographic market while leveraging transitional collaborations to accelerate access and capability building.

Strategic company-level analysis showing how platform consolidation, specialized molecular innovators, and service labs are reshaping competitive positioning and partnership models

Company-level dynamics in hematologic malignancies testing show a balance between established diagnostics firms, emerging molecular players, and specialized service laboratories. Leading diagnostics manufacturers continue to invest in platform consolidation, workflow automation, and assay breadth to serve hospital networks and high-volume reference labs, while smaller molecular diagnostics firms focus on niche panels, advanced sequencing workflows, and bioinformatics capabilities that enable precision medicine applications. Strategic partnerships between instrument providers and reagent specialists are increasingly common, creating bundled solutions that reduce operational friction and accelerate laboratory onboarding.

Service laboratories are differentiating through expanded test menus, faster reporting, and consultative interpretive services that support clinicians in complex cases. At the same time, commercial strategies emphasize value demonstration-showing how diagnostic data improves treatment selection, reduces downstream utilization, and supports payer conversations. As a result, companies that combine robust analytical performance with strong implementation support, local regulatory expertise, and flexible commercial models are better positioned to capture demand in diverse care settings and to respond to evolving clinical needs.

Practical and prioritized recommendations for laboratory leaders and diagnostic vendors to build supply resilience, digital integration, and clinical alignment for sustained adoption

Industry leaders should prioritize a coherent set of actions that balance near-term operational continuity with long-term capability building. First, supply chain diversification and close supplier collaboration will mitigate tariff and logistics risks; laboratories and vendors should jointly map critical component dependencies and establish redundant sourcing or local manufacturing partnerships where feasible. Second, investments in automation and informatics should be targeted to reduce manual touchpoints and enable scalable interpretation workflows that integrate cytogenetic, flow, immunohistochemical, and molecular data for coherent clinical reporting.

Moreover, organizations should strengthen clinical-laboratory partnerships to align test menus with evolving treatment paradigms across leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, ensuring that sample handling and turnaround commitments meet clinician needs. Finally, adopting flexible commercial models-such as outcome-linked services, bundled solutions, and subscription-based access to reference data-will help laboratories and vendors demonstrate value to payers and providers. In sum, actionable leadership requires coordinated investments across procurement, technology, clinical integration, and commercial innovation to sustain diagnostic excellence.

A transparent mixed-methods research approach combining primary stakeholder interviews, technical validation, and contextual analysis to ensure robust and actionable conclusions

The research methodology underpinning this analysis employed a multi-source, mixed-methods approach combining primary interviews with laboratory directors, clinical specialists, procurement leaders, and industry executives alongside a systematic review of regulatory guidance, technical validation literature, and public company disclosures. Data synthesis emphasized triangulation to reconcile supplier statements, laboratory practice patterns, and clinical guidelines, ensuring that observations reflect operational realities rather than vendor positioning. Qualitative insights were augmented by case studies that illustrate how laboratories deploy integrated testing strategies across blood and bone marrow specimens and across laboratory-based and point-of-care testing modes.

Throughout the research process, care was taken to validate technical claims regarding assay performance, sample handling, and workflow integration against peer-reviewed literature and consensus diagnostic frameworks. The methodology prioritized transparency in source attribution and applied structured analysis to identify directional trends, risk factors such as tariff impacts, and practical implications for end users including academic centers, hospitals, and reference laboratories. This rigorous combination of stakeholder insight, technical validation, and contextual analysis supports actionable conclusions for decision-makers.

A succinct conclusion emphasizing how integrated diagnostics, supply resilience, and strategic commercialization will determine clinical impact and operational sustainability

In conclusion, hematologic malignancies testing is evolving into an integrated, multimodal ecosystem where cytogenetics, flow cytometry, immunohistochemistry, and molecular diagnostics converge to provide richer, clinically actionable insights. Laboratories and vendors must navigate tariff-driven supply chain shifts, regulatory complexities, and heterogeneous regional adoption patterns while investing in automation, interoperability, and clinician-focused reporting. The convergence of technologies and growing demand across leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes create opportunities for differentiated solutions that prioritize clinical utility and operational scalability.

Looking ahead, stakeholders who align their product development, commercialization, and operational strategies with the nuanced needs of academic and research institutes, hospitals and clinics, and reference laboratories will be best positioned to accelerate clinical impact. By emphasizing resilient sourcing, robust validation, and flexible commercial models, industry players can translate diagnostic advancements into improved patient care pathways and sustainable laboratory operations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hematologic Malignancies Testing Market, by Technology

  • 8.1. Cytogenetics
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Karyotyping
  • 8.2. Flow Cytometry
  • 8.3. Immunohistochemistry
    • 8.3.1. Liquid Based
    • 8.3.2. Tissue Based
  • 8.4. Molecular Diagnostics
    • 8.4.1. Fluorescence In Situ Hybridization
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Polymerase Chain Reaction

9. Hematologic Malignancies Testing Market, by Sample Type

  • 9.1. Blood
  • 9.2. Bone Marrow

10. Hematologic Malignancies Testing Market, by Test Mode

  • 10.1. Laboratory Based
  • 10.2. Point Of Care

11. Hematologic Malignancies Testing Market, by Application

  • 11.1. Leukemia
  • 11.2. Lymphoma
  • 11.3. Multiple Myeloma
  • 11.4. Myelodysplastic Syndromes

12. Hematologic Malignancies Testing Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Hospitals & Clinics
  • 12.3. Reference Laboratories

13. Hematologic Malignancies Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hematologic Malignancies Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hematologic Malignancies Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Hematologic Malignancies Testing Market

17. China Hematologic Malignancies Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Adaptive Biotechnologies
  • 18.7. Agilent Technologies, Inc.
  • 18.8. Beckman Coulter, Inc.
  • 18.9. Becton, Dickinson and Company
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. HORIBA, Ltd.
  • 18.13. ICON PLC
  • 18.14. Illumina, Inc.
  • 18.15. Invitae Corporation
  • 18.16. Invivoscribe, Inc.
  • 18.17. Laboratory Corporation of America Holdings
  • 18.18. Leica Biosystems Nussloch GmbH
  • 18.19. Myriad Genetics, Inc.
  • 18.20. Natera, Inc.
  • 18.21. Nikon Instruments
  • 18.22. Ortho Clinical Diagnostics
  • 18.23. PerkinElmer Corporation
  • 18.24. QIAGEN N.V.
  • 18.25. Siemens AG
  • 18.26. Sysmex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 164. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 191. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 200. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)